vs
Side-by-side financial comparison of Orthofix Medical Inc. (OFIX) and Shake Shack Inc. (SHAK). Click either name above to swap in a different company.
Shake Shack Inc. is the larger business by last-quarter revenue ($400.5M vs $219.9M, roughly 1.8× Orthofix Medical Inc.). Shake Shack Inc. runs the higher net margin — 3.0% vs -1.0%, a 4.0% gap on every dollar of revenue. On growth, Shake Shack Inc. posted the faster year-over-year revenue change (21.9% vs 2.0%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $4.0M). Over the past eight quarters, Shake Shack Inc.'s revenue compounded faster (17.4% CAGR vs 8.0%).
Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.
Shake Shack is an American multinational fast casual restaurant chain based in New York City. It started out as a hot dog cart inside Madison Square Park in 2001, and its popularity steadily grew. In 2004, it received a permit to open a permanent kiosk within the park, expanding its menu from New York–style hot dogs to one with hamburgers, hot dogs, fries and its namesake milkshakes.
OFIX vs SHAK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $219.9M | $400.5M |
| Net Profit | $-2.2M | $11.8M |
| Gross Margin | 71.1% | — |
| Operating Margin | 0.2% | 4.7% |
| Net Margin | -1.0% | 3.0% |
| Revenue YoY | 2.0% | 21.9% |
| Net Profit YoY | 92.4% | 35.8% |
| EPS (diluted) | $-0.05 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $219.9M | $400.5M | ||
| Q3 25 | $205.6M | $367.4M | ||
| Q2 25 | $203.1M | $356.5M | ||
| Q1 25 | $193.6M | $320.9M | ||
| Q4 24 | $215.7M | $328.7M | ||
| Q3 24 | $196.6M | $316.9M | ||
| Q2 24 | $198.6M | $316.5M | ||
| Q1 24 | $188.6M | $290.5M |
| Q4 25 | $-2.2M | $11.8M | ||
| Q3 25 | $-22.8M | $12.5M | ||
| Q2 25 | $-14.1M | $17.1M | ||
| Q1 25 | $-53.1M | $4.2M | ||
| Q4 24 | $-29.1M | $8.7M | ||
| Q3 24 | $-27.4M | $-10.2M | ||
| Q2 24 | $-33.4M | $9.7M | ||
| Q1 24 | $-36.0M | $2.0M |
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
| Q4 25 | 0.2% | 4.7% | ||
| Q3 25 | -8.3% | 5.0% | ||
| Q2 25 | -7.9% | 6.3% | ||
| Q1 25 | -25.2% | 0.9% | ||
| Q4 24 | -5.3% | 3.1% | ||
| Q3 24 | -9.6% | -5.7% | ||
| Q2 24 | -12.5% | 3.4% | ||
| Q1 24 | -15.6% | 0.0% |
| Q4 25 | -1.0% | 3.0% | ||
| Q3 25 | -11.1% | 3.4% | ||
| Q2 25 | -6.9% | 4.8% | ||
| Q1 25 | -27.4% | 1.3% | ||
| Q4 24 | -13.5% | 2.6% | ||
| Q3 24 | -13.9% | -3.2% | ||
| Q2 24 | -16.8% | 3.1% | ||
| Q1 24 | -19.1% | 0.7% |
| Q4 25 | $-0.05 | $0.28 | ||
| Q3 25 | $-0.57 | $0.30 | ||
| Q2 25 | $-0.36 | $0.41 | ||
| Q1 25 | $-1.35 | $0.10 | ||
| Q4 24 | $-0.76 | $0.22 | ||
| Q3 24 | $-0.71 | $-0.26 | ||
| Q2 24 | $-0.88 | $0.23 | ||
| Q1 24 | $-0.95 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.0M | $360.1M |
| Total DebtLower is stronger | — | $247.7M |
| Stockholders' EquityBook value | $450.0M | $525.3M |
| Total Assets | $850.6M | $1.9B |
| Debt / EquityLower = less leverage | — | 0.47× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.0M | $360.1M | ||
| Q3 25 | $62.9M | $357.8M | ||
| Q2 25 | $65.6M | $336.8M | ||
| Q1 25 | $58.0M | $312.9M | ||
| Q4 24 | $83.2M | $320.7M | ||
| Q3 24 | $30.1M | $310.9M | ||
| Q2 24 | $26.4M | $304.4M | ||
| Q1 24 | $27.0M | $284.8M |
| Q4 25 | — | $247.7M | ||
| Q3 25 | $157.2M | $247.5M | ||
| Q2 25 | $157.0M | $247.2M | ||
| Q1 25 | $156.9M | $246.9M | ||
| Q4 24 | $157.0M | $246.7M | ||
| Q3 24 | $118.5M | $246.4M | ||
| Q2 24 | $118.0M | $246.2M | ||
| Q1 24 | $118.2M | $245.9M |
| Q4 25 | $450.0M | $525.3M | ||
| Q3 25 | $442.5M | $509.0M | ||
| Q2 25 | $458.3M | $494.1M | ||
| Q1 25 | $458.3M | $473.3M | ||
| Q4 24 | $503.1M | $470.0M | ||
| Q3 24 | $525.9M | $456.1M | ||
| Q2 24 | $546.0M | $462.4M | ||
| Q1 24 | $570.3M | $446.4M |
| Q4 25 | $850.6M | $1.9B | ||
| Q3 25 | $832.6M | $1.8B | ||
| Q2 25 | $837.2M | $1.8B | ||
| Q1 25 | $823.1M | $1.7B | ||
| Q4 24 | $893.3M | $1.7B | ||
| Q3 24 | $867.9M | $1.7B | ||
| Q2 24 | $882.0M | $1.7B | ||
| Q1 24 | $906.0M | $1.6B |
| Q4 25 | — | 0.47× | ||
| Q3 25 | 0.36× | 0.49× | ||
| Q2 25 | 0.34× | 0.50× | ||
| Q1 25 | 0.34× | 0.52× | ||
| Q4 24 | 0.31× | 0.52× | ||
| Q3 24 | 0.23× | 0.54× | ||
| Q2 24 | 0.22× | 0.53× | ||
| Q1 24 | 0.21× | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.7M | $63.1M |
| Free Cash FlowOCF − Capex | $16.8M | $4.0M |
| FCF MarginFCF / Revenue | 7.6% | 1.0% |
| Capex IntensityCapex / Revenue | 4.9% | 14.8% |
| Cash ConversionOCF / Net Profit | — | 5.34× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.3M | $56.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.7M | $63.1M | ||
| Q3 25 | $12.4M | $63.0M | ||
| Q2 25 | $11.6M | $65.0M | ||
| Q1 25 | $-18.4M | $31.2M | ||
| Q4 24 | $23.7M | $45.1M | ||
| Q3 24 | $11.7M | $41.9M | ||
| Q2 24 | $9.0M | $53.5M | ||
| Q1 24 | $-18.6M | $30.7M |
| Q4 25 | $16.8M | $4.0M | ||
| Q3 25 | $2.5M | $23.7M | ||
| Q2 25 | $4.5M | $26.9M | ||
| Q1 25 | $-25.1M | $1.9M | ||
| Q4 24 | $15.2M | $10.4M | ||
| Q3 24 | $6.3M | $7.1M | ||
| Q2 24 | $-360.0K | $20.6M | ||
| Q1 24 | $-29.1M | $-2.4M |
| Q4 25 | 7.6% | 1.0% | ||
| Q3 25 | 1.2% | 6.5% | ||
| Q2 25 | 2.2% | 7.5% | ||
| Q1 25 | -13.0% | 0.6% | ||
| Q4 24 | 7.0% | 3.2% | ||
| Q3 24 | 3.2% | 2.2% | ||
| Q2 24 | -0.2% | 6.5% | ||
| Q1 24 | -15.4% | -0.8% |
| Q4 25 | 4.9% | 14.8% | ||
| Q3 25 | 4.8% | 10.7% | ||
| Q2 25 | 3.5% | 10.7% | ||
| Q1 25 | 3.5% | 9.1% | ||
| Q4 24 | 4.0% | 10.6% | ||
| Q3 24 | 2.7% | 11.0% | ||
| Q2 24 | 4.7% | 10.4% | ||
| Q1 24 | 5.6% | 11.4% |
| Q4 25 | — | 5.34× | ||
| Q3 25 | — | 5.04× | ||
| Q2 25 | — | 3.79× | ||
| Q1 25 | — | 7.36× | ||
| Q4 24 | — | 5.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.54× | ||
| Q1 24 | — | 15.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
SHAK
Segment breakdown not available.
